| THE DETERMINANTS OF PRICING IN PHARMACEUTICALS: ARE US PRICES REALLY SO HIGH? | |
| | |
MedLine Citation:
|
PMID: 23303712 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
This paper studies price determination in pharmaceutical markets using data for 25 countries, 6 years, and a comprehensive list of products from the MIDAS IMS database. A key finding is that the USA has prices that are not significantly higher than those of countries with similar income levels, especially those that are 'lightly regulated'. More importantly, price differences to the US levels increase for 'branded', world top selling, or innovative products, and decrease, regardless of the level of regulation for mature or widely diffused molecules. Because prices for top selling molecules may be easier to perceive and recollect and more important for companies, they may bias the public discussion about international price differences. Copyright © 2013 John Wiley & Sons, Ltd. |
| | |
Authors:
|
Antonio Cabrales; Sergi Jiménez-Martín |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-1-10 |
Journal Detail:
|
Title: Health economics Volume: - ISSN: 1099-1050 ISO Abbreviation: Health Econ Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-1-10 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9306780 Medline TA: Health Econ Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2013 John Wiley & Sons, Ltd. |
Affiliation:
|
Universidad Carlos III de Madrid, Economics, Spain. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Membrane Microreactors: Gas-Liquid Reactions Made Easy.
Next Document: Proteomic methods reveal cyclophilin a functions as a host restriction factor against rotavirus infe...